The role of statins as potential targets for bone formation

Arthritis Research

Volumn 4, Issue 4, 2002, Pages 237-240

  Garrett, I Ross ^a   Mundy, Greg R ^b  

^a OsteoScreen   (United States)

^b CTRC Institute for Drug Development   (United States)

Author keywords

Bone formation; HMG CoA reductase; Inhibitors; Osteoblasts; Osteoporosis; Statins

Indexed keywords

ANABOLIC AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN 2; CALCITONIN; CERIVASTATIN; COMPACTIN; ESTROGEN; ESTROGEN DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IPRIFLAVONE; MEVINOLIN; PRAVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOSCLEROSIS; ARTICLE; AUTOCRINE EFFECT; BONE ATROPHY; BONE CELL; BONE MASS; CELL DIFFERENTIATION; CLINICAL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; FRACTURE; GENE EXPRESSION; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PARACRINE SIGNALING; RAT; RISK MANAGEMENT; TRANSDERMAL PATCH;

ANIMAL; ANIMALS; ANIMALS, NEWBORN; BONE AND BONES; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; FEMALE; FRACTURES, SPONTANEOUS; HUMAN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO; MICE; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; RATS; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035985804     PISSN: 14659905     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar413     Document Type: Article

References (28)

1. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
2. Research and development of pravastatin
3. Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia
4. Therapeutic efficacy of the lipid-lowering armamentarium: The clinical benefits of aggressive lipid-lowering therapy
5. The organizational and structure of bone and the mechanism of calcification
6. Comparison, structure and organization of bone and other mineralized tissues and the mechanism of calcification
7. The effects of cytokines and growth factors on osteoblastic cells
8. Bone morphogenetic proteins
9. Effects of transforming growth factor beta on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagen mRNA in long-term cultures of osteoblasts
10. Immortalized murine osteoblasts derived from BMP 2-T-antigen expressing transgenic mice
11. Stimulation of bone formation in vitro and in rodents by statins
12. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
13. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells
14. Cerivastatin increases cortical bone formation in OVX rats
15. Simvastatin given orally to adult rats increases the compressive strength of vertebral bodies
16. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase
17. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase
18. Statins mediate their effects on osteoblasts by inhibition of HMG-CoA reductase and ultimately BMP2
19. Statin use, bone mass and fracture: An analysis of two prospective studies
20. Oral statins and increased bone-mineral density in postmenopausal women
21. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
22. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
23. HMG-CoA reductase inhibitors and the risk of fractures
24. Statin drugs and the risk of fracture
25. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
26. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study
27. Use of statins and risk of fractures
28. Statin use and bone mineral density (BMD) in older women: The Women's Health Initiative Observational Study (WH I-OS)